Background: Disease-modifying therapies (DMTs) have transformed the natural history of spinal muscular atrophy (SMA) type 1, revealing heterogeneous developmental trajectories and renewing interest in cognitive and language outcomes beyond gross motor function. Within an embodied cognition framework, sensorimotor exper...
Sofia Biagi, L. Rinaldi, M. Arnoldi et al.· Journal of Clinical Medicine· 0 citations
PURPOSE
Spinal muscular atrophy Type 1 (SMA1) is a rare autosomal recessive neuromuscular disorder with progressive muscle weakness and atrophy. Dysphagia is common among children with SMA1, and its complications are frequently documented. This scoping review aimed to describe the management of swallowing disorders in...
Sara Rocca, Laura Pizzi, Nicole Pizzorni et al.· American Journal of Speech-L...· 0 citations
Standardised and clinically meaningful swallowing outcome measures are lacking, limiting comparability across studies and future research should prioritise the development of structured dysphagia rehabilitation protocols and standardised, clinically meaningful outcome measures.
Sofia Gandolfi, Chiara Andriani, Éadaoin Flynn et al.· Advances in Communication an...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.